Originaltext
Diese Übersetzung bewerten
Mit deinem Feedback können wir Google Übersetzer weiter verbessern
Home
Pnc Financial Services Group, Inc. (the)
Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility
Business
Nov 6 2025
27 min read

Trupanion Reports Strong Third Quarter 2025 Results and Secures New Credit Facility

news images

SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Trupanion, Inc. (Nasdaq: TRUP), a leading provider of medical insurance for cats and dogs, today announced financial results for the third quarter ended September 30, 2025.

“We delivered record quarterly profitability while accelerating subscription pet growth for the third consecutive quarter,” said Margi Tooth, Chief Executive Officer and President of Trupanion. “With a strong financial foundation, we have the flexibility to invest where it matters most - driving sustainable growth and expanding access to care. Our disciplined model continues to generate meaningful cash flow, positioning us to build on this momentum in the quarters ahead.”

TRUP ER Pic Q3'25


Third Quarter 2025 Financial and Business Highlights

  • Total revenue was $366.9 million, an increase of 12% compared to the third quarter of 2024.

  • Total enrolled pets (including pets from our other business segment) was 1,654,414 at September 30, 2025, a decrease of 2% over September 30, 2024.

  • Subscription business revenue was $252.7 million, an increase of 15% compared to the third quarter of 2024.

  • Subscription enrolled pets was 1,082,412 at September 30, 2025, an increase of 5% over September 30, 2024.

  • Net income was $5.9 million, or $0.14 per basic and $0.13 per diluted share, compared to net income of $1.4 million, or $0.03 per basic and diluted share, in the third quarter of 2024.

  • Adjusted EBITDA was $19.6 million, compared to adjusted EBITDA of $14.5 million in the third quarter of 2024.

  • Operating cash flow was $29.2 million and free cash flow was $23.9 million in the third quarter of 2025. This compared to operating cash flow of $15.3 million and free cash flow of $13.4 million in the third quarter of 2024.

First Nine Months 2025 Financial and Business Highlights

  • Total revenue was $1,062.5 million, an increase of 12% compared to the first nine months of 2024.

  • Subscription business revenue was $727.9 million, an increase of 16% compared to the first nine months of 2024.

  • Net income was $13.8 million, or $0.32 per basic and per diluted share, compared to net loss of $(11.3) million, or $(0.27) per basic and diluted share, in the first nine months of 2024.

  • Adjusted EBITDA was $48.4 million, compared to adjusted EBITDA of $26.7 million in the first nine months of 2024.

  • Operating cash flow was $60.2 million and free cash flow was $50.0 million in the first nine months of 2025. This compared to operating cash flow of $24.6 million and free cash flow of $16.7 million in the first nine months of 2024.

  • At September 30, 2025, the Company held $348.5 million in cash and short-term investments, including $58.5 million held outside the insurance entities, with an additional $15.0 million available under its credit facility.

New Credit Facility with PNC Bank
Trupanion announced today the successful completion of a debt transaction that further enhances the company’s financial flexibility and long-term growth capacity. As part of this transaction, Trupanion entered into a new credit agreement with PNC Bank, N.A., a member of the PNC Financial Services Group, Inc. (NYSE: PNC), one of the largest diversified financial services institutions in the United States. The new three-year $120 million credit facility was used to repay the prior credit facility and has a lower interest rate, which provides additional savings to support Trupanion’s strategic initiatives and operational investments.

“This new lower-cost credit facility, established with a trusted financial institution like PNC Bank, marks another important step in strengthening our capital structure,” said Fawwad Qureshi, Chief Financial Officer of Trupanion. “It provides us with greater flexibility to allocate capital toward opportunities that drive long-term shareholder value. This transaction reflects the progress we’ve made in strengthening our balance sheet over the last two years and positions us well for continued investment in sustainable growth.”

The transaction underscores Trupanion’s ongoing commitment to prudent financial management as the company continues to expand its reach across North America and beyond, helping more pets gain access to high-quality medical care when they need it most.

Conference Call
Trupanion’s management will host a conference call today to review its third quarter 2025 results. The call is scheduled to begin shortly after 1:30 p.m. PT/ 4:30 p.m. ET. A live webcast will be accessible through the Investor Relations section of Trupanion’s website at https://investors.trupanion.com/ and will be archived online for 3 months upon completion of the conference call. Participants can access the conference call by dialing 1-844-676-1342 (United States) or 1-412-634-6683 (International). A telephonic replay of the call will also be available after the completion of the call, by dialing 1-844-512-2921 (United States) or 1-412-317-6671 (International) and entering the replay pin number: 10203296.

About Trupanion
Trupanion is a leader in medical insurance for cats and dogs throughout the United States, Canada, and certain countries in Continental Europe with over 1,000,000 pets currently enrolled. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. Trupanion is committed to providing pet parents with the highest value in pet medical insurance with unlimited payouts for the life of their pets. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company or ZPIC Insurance Company and, in Canada, by Accelerant Insurance Company of Canada or GPIC Insurance Company. Policies are sold and administered in Canada by Canada Pet Health Insurance Services, Inc. dba Trupanion 309-1277 Lynn Valley Road, North Vancouver, BC V7J 0A2 and in the United States by Trupanion Managers USA, Inc. (CA license No. 0G22803, NPN 9588590). Canada Pet Health Insurance Services, Inc. is a registered damage insurance agency and claims adjuster in Quebec #603927. For more information, please visit trupanion.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and financial results for Trupanion, including, but not limited to, its expectations regarding its ability to continue to grow its enrollments and revenue, and otherwise execute its business plan. These forward-looking statements are based upon the current expectations and beliefs of Trupanion’s management as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. All forward-looking statements made in this press release are based on information available to Trupanion as of the date hereof, and Trupanion has no obligation to update these forward-looking statements.

In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the ability to achieve or maintain profitability and/or appropriate levels of cash flow in future periods; the ability to keep growing our membership base and revenue; the accuracy of assumptions used in determining appropriate member acquisition expenditures; the severity and frequency of claims; the ability to maintain high retention rates; the accuracy of assumptions used in pricing medical plan subscriptions and the ability to accurately estimate the impact of new products or offerings on claims frequency; actual claims expense exceeding estimates; regulatory and other constraints on the ability to institute, or the decision to otherwise delay, pricing modifications in response to changes in actual or estimated claims expense; the effectiveness and statutory or regulatory compliance of our Territory Partner model and of our Territory Partners, veterinarians and other third parties in recommending medical plan subscriptions to potential members; the ability to retain existing Territory Partners and increase the number of Territory Partners and active hospitals; compliance by us and those referring us members with laws and regulations that apply to our business, including the sale of a pet medical plan; the ability to maintain the security of our data; fluctuations in the Canadian currency exchange rate; the ability to protect our proprietary and member information; the ability to maintain our culture and team; the ability to maintain the requisite amount of risk-based capital; our ability to generate sufficient cash flows to repay or otherwise comply with requirements of our outstanding debt; our ability to implement and maintain effective controls, including to remediate material weaknesses in internal controls over financial reporting; the ability to protect and enforce Trupanion’s intellectual property rights; the ability to successfully implement our alliance with Aflac; our ability to successfully finalize the transition of policies from Accelerant to our wholly owned subsidiary, GPIC; the ability to continue key contractual relationships with third parties; third-party claims including litigation and regulatory actions; the ability to recognize benefits from investments in new solutions and enhancements to Trupanion’s technology platform and website; our ability to retain key personnel; and deliberations and determinations by the Trupanion board based on the future performance of the company or otherwise.

For a detailed discussion of these and other cautionary statements, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K. All documents are available through the SEC’s Electronic Data Gathering Analysis and Retrieval system at https://www.sec.gov or the Investor Relations section of Trupanion’s website at https://investors.trupanion.com.

Non-GAAP Financial Measures
Trupanion’s stated results may include certain non-GAAP financial measures. These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in its industry as other companies in its industry may calculate or use non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies and exclude expenses that may have a material impact on Trupanion’s reported financial results. The presentation and utilization of non-GAAP financial measures is not meant to be considered in isolation or as a substitute for the directly comparable financial measures prepared in accordance with GAAP. Trupanion urges its investors to review the reconciliation of its non-GAAP financial measures to the most directly comparable GAAP financial measures in its consolidated financial statements, and not to rely on any single financial or operating measure to evaluate its business. These reconciliations are included below and on Trupanion’s Investor Relations website.

Because of varying available valuation methodologies, subjective assumptions and the variety of equity instruments that can impact a company’s non-cash expenses, Trupanion believes that providing various non-GAAP financial measures that exclude stock-based compensation expense and depreciation and amortization expense allows for more meaningful comparisons between its operating results from period to period. Trupanion offsets new pet acquisition expense with sign-up fee revenue in the calculation of net acquisition cost because it collects sign-up fee revenue from new members at the time of enrollment and considers it to be an offset to a portion of Trupanion’s new pet acquisition expense. Trupanion believes this allows it to calculate and present financial measures in a consistent manner across periods. Trupanion’s management believes that the non-GAAP financial measures and the related financial measures derived from them are important tools for financial and operational decision-making and for evaluating operating results over different periods of time.

Trupanion, Inc.
Condensed Consolidated Statements of Operations
(in thousands, except share data)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

 

(unaudited)

Revenue:

 

 

 

 

 

 

 

Subscription business

$

252,697

 

 

$

218,986

 

 

$

727,917

 

 

$

628,738

 

Other business

 

114,223

 

 

 

108,470

 

 

 

334,535

 

 

 

319,639

 

Total revenue

 

366,920

 

 

 

327,456

 

 

 

1,062,452

 

 

 

948,377

 

Cost of revenue:

 

 

 

 

 

 

 

Subscription business

 

200,766

 

 

 

177,365

 

 

 

586,098

 

 

 

525,237

 

Other business

 

106,100

 

 

 

100,712

 

 

 

310,370

 

 

 

297,265

 

Total cost of revenue(1), (2)

 

306,866

 

 

 

278,077

 

 

 

896,468

 

 

 

822,502

 

Operating expenses:

 

 

 

 

 

 

 

Technology and development(1)

 

9,887

 

 

 

7,933

 

 

 

26,545

 

 

 

23,083

 

General and administrative(1)

 

18,311

 

 

 

16,977

 

 

 

58,325

 

 

 

46,903

 

New pet acquisition expense(1)

 

21,946

 

 

 

18,308

 

 

 

62,305

 

 

 

53,025

 

Depreciation and amortization

 

4,051

 

 

 

4,381

 

 

 

11,804

 

 

 

12,542

 

Total operating expenses

 

54,195

 

 

 

47,599

 

 

 

158,979

 

 

 

135,553

 

Loss from investment in joint venture

 

 

 

 

(34

)

 

 

(305

)

 

 

(184

)

Operating income (loss)

 

5,859

 

 

 

1,746

 

 

 

6,700

 

 

 

(9,862

)

Interest expense

 

2,790

 

 

 

3,820

 

 

 

9,683

 

 

 

11,071

 

Other (income), net

 

(3,530

)

 

 

(3,538

)

 

 

(18,684

)

 

 

(9,601

)

Income (loss) before income taxes

 

6,599

 

 

 

1,464

 

 

 

15,701

 

 

 

(11,332

)

Income tax (benefit) expense

 

726

 

 

 

39

 

 

 

1,898

 

 

 

(43

)

Net income (loss)

$

5,873

 

 

$

1,425

 

 

$

13,803

 

 

$

(11,289

)

 

 

 

 

 

 

 

 

Net income (loss) per share:

 

 

 

 

 

 

 

Basic

$

0.14

 

 

$

0.03

 

 

$

0.32

 

 

$

(0.27

)

Diluted

$

0.13

 

 

$

0.03

 

 

$

0.32

 

 

$

(0.27

)

Weighted average shares of common stock outstanding:

 

 

 

 

 

 

 

Basic

 

43,076,695

 

 

 

42,233,903

 

 

 

42,849,769

 

 

 

42,076,998

 

Diluted

 

43,562,132

 

 

 

42,822,505

 

 

 

43,550,326

 

 

 

42,076,998

 

 

 

 

 

 

 

 

 

(1)Includes stock-based compensation expense as follows:

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Veterinary invoice expense

$

677

 

 

$

847

 

 

$

2,221

 

 

$

2,625

 

Other cost of revenue

 

585

 

 

 

554

 

 

 

1,679

 

 

 

1,561

 

Technology and development

 

1,705

 

 

 

1,259

 

 

 

4,326

 

 

 

3,774

 

General and administrative

 

4,971

 

 

 

4,125

 

 

 

14,546

 

 

 

11,435

 

New pet acquisition expense

 

1,561

 

 

 

1,555

 

 

 

6,013

 

 

 

5,743

 

Total stock-based compensation expense

$

9,499

 

 

$

8,340

 

 

$

28,785

 

 

$

25,138

 

 

 

 

 

 

 

 

 

(2)The breakout of cost of revenue between veterinary invoice expense and other cost of revenue is as follows:

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Veterinary invoice expense

$

263,127

 

 

$

238,814

 

 

$

766,157

 

 

$

703,485

 

Other cost of revenue

 

43,739

 

 

 

39,263

 

 

 

130,311

 

 

 

119,017

 

Total cost of revenue

$

306,866

 

 

$

278,077

 

 

$

896,468

 

 

$

822,502

 


 

Trupanion, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share data)

 

September 30, 2025

 

December 31, 2024

 

(unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

154,773

 

 

$

160,295

 

Short-term investments

 

193,761

 

 

 

147,089

 

Accounts and other receivables, net of allowance for credit losses of $1,595 at September 30, 2025 and $1,117 at December 31, 2024

 

302,534

 

 

 

274,031

 

Prepaid expenses and other assets

 

16,963

 

 

 

15,912

 

Total current assets

 

668,031

 

 

 

597,327

 

Restricted cash

 

34,136

 

 

 

39,235

 

Long-term investments

 

981

 

 

 

373

 

Property, equipment, and internal-use software, net

 

104,683

 

 

 

102,191

 

Intangible assets, net

 

24,772

 

 

 

13,177

 

Other long-term assets

 

7,186

 

 

 

17,579

 

Goodwill

 

40,384

 

 

 

36,971

 

Total assets

$

880,173

 

 

$

806,853

 

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

12,760

 

 

$

11,532

 

Accrued liabilities and other current liabilities

 

43,577

 

 

 

33,469

 

Reserve for veterinary invoices

 

53,972

 

 

 

51,635

 

Deferred revenue

 

279,713

 

 

 

251,640

 

Long-term debt - current portion

 

750

 

 

 

1,350

 

Total current liabilities

 

390,772

 

 

 

349,626

 

Long-term debt

 

113,790

 

 

 

127,537

 

Deferred tax liabilities

 

2,252

 

 

 

1,946

 

Other liabilities

 

4,797

 

 

 

4,476

 

Total liabilities

 

511,611

 

 

 

483,585

 

Stockholders’ equity:

 

 

 

Common stock: $0.00001 par value per share, 100,000,000 shares authorized; 44,220,625 and 43,192,339 issued and outstanding at September 30, 2025; 43,516,631 and 42,488,445 shares issued and outstanding at December 31, 2024

 

 

 

 

 

Preferred stock: $0.00001 par value per share, 10,000,000 shares authorized; no shares issued and outstanding

 

 

 

 

 

Additional paid-in capital

 

595,802

 

 

 

568,302

 

Accumulated other comprehensive income (loss)

 

1,379

 

 

 

(2,612

)

Accumulated deficit

 

(212,085

)

 

 

(225,888

)

Treasury stock, at cost: 1,028,186 shares at September 30, 2025 and December 31, 2024

 

(16,534

)

 

 

(16,534

)

Total stockholders’ equity

 

368,562

 

 

 

323,268

 

Total liabilities and stockholders’ equity

$

880,173

 

 

$

806,853

 


 

Trupanion, Inc.
Condensed Consolidated Statements of Cash Flows
(in thousands)

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

 

(unaudited)

Operating activities

 

 

 

 

 

 

 

Net income (loss)

$

5,873

 

 

$

1,425

 

 

$

13,803

 

 

$

(11,289

)

Adjustments to reconcile net income (loss) to cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

4,051

 

 

 

4,381

 

 

 

11,804

 

 

 

12,542

 

Stock-based compensation expense

 

9,499

 

 

 

8,341

 

 

 

28,785

 

 

 

25,138

 

Realized gain on nonmonetary exchange of preferred stock investment

 

 

 

 

 

 

 

(7,783

)

 

 

 

Other, net

 

215

 

 

 

(136

)

 

 

1,164

 

 

 

(453

)

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts and other receivables

 

(9,912

)

 

 

(3,794

)

 

 

(27,927

)

 

 

(22,020

)

Prepaid expenses and other assets

 

44

 

 

 

101

 

 

 

(540

)

 

 

2,398

 

Accounts payable, accrued liabilities, and other liabilities

 

10,026

 

 

 

1,377

 

 

 

11,017

 

 

 

(350

)

Reserve for veterinary invoices

 

1,538

 

 

 

(3,934

)

 

 

2,235

 

 

 

(6,469

)

Deferred revenue

 

7,904

 

 

 

7,535

 

 

 

27,668

 

 

 

25,088

 

Net cash provided by operating activities

 

29,238

 

 

 

15,296

 

 

 

60,226

 

 

 

24,585

 

Investing activities

 

 

 

 

 

 

 

Purchases of investment securities

 

(41,020

)

 

 

(26,125

)

 

 

(183,021

)

 

 

(107,375

)

Maturities and sales of investment securities

 

43,563

 

 

 

26,089

 

 

 

137,827

 

 

 

81,767

 

Purchases of property, equipment, and internal-use software

 

(5,302

)

 

 

(1,914

)

 

 

(10,206

)

 

 

(7,858

)

Other

 

437

 

 

 

490

 

 

 

1,639

 

 

 

1,552

 

Net cash used in investing activities

 

(2,322

)

 

 

(1,460

)

 

 

(53,761

)

 

 

(31,914

)

Financing activities

 

 

 

 

 

 

 

Repayment of debt financing

 

(188

)

 

 

(338

)

 

 

(15,713

)

 

 

(1,013

)

Proceeds from exercise of stock options

 

80

 

 

 

258

 

 

 

1,407

 

 

 

729

 

Shares withheld to satisfy tax withholding

 

(1,179

)

 

 

(802

)

 

 

(2,867

)

 

 

(1,390

)

Other

 

(154

)

 

 

(157

)

 

 

(614

)

 

 

(609

)

Net cash used in financing activities

 

(1,441

)

 

 

(1,039

)

 

 

(17,787

)

 

 

(2,283

)

Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net

 

(1,037

)

 

 

481

 

 

 

701

 

 

 

19

 

Net change in cash, cash equivalents, and restricted cash

 

24,438

 

 

 

13,278

 

 

 

(10,621

)

 

 

(9,593

)

Cash, cash equivalents, and restricted cash at beginning of period

 

164,471

 

 

 

147,593

 

 

 

199,530

 

 

 

170,464

 

Cash, cash equivalents, and restricted cash at end of period

$

188,909

 

 

$

160,871

 

 

$

188,909

 

 

$

160,871

 


 

The following tables set forth our key operating metrics.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended
September 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

Total Business:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total pets enrolled (at period end)

 

1,654,414

 

 

 

1,688,903

 

 

 

 

 

 

 

 

 

 

 

 

 

Subscription Business:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total subscription pets enrolled (at period end)

 

1,082,412

 

 

 

1,032,042

 

 

 

 

 

 

 

 

 

 

 

 

 

Monthly average revenue per pet

$

79.84

 

 

$

71.94

 

 

 

 

 

 

 

 

 

 

 

 

 

Average pet acquisition cost (PAC)

$

278

 

 

$

227

 

 

 

 

 

 

 

 

 

 

 

 

 

Average monthly retention

 

98.33

%

 

 

98.29

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Sep. 30, 2025

 

Jun. 30, 2025

 

Mar. 31, 2025

 

Dec. 31, 2024

 

Sep. 30, 2024

 

Jun. 30, 2024

 

Mar. 31, 2024

 

Dec. 31, 2023

Total Business:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total pets enrolled (at period end)

 

1,654,414

 

 

 

1,660,455

 

 

 

1,667,637

 

 

 

1,677,570

 

 

 

1,688,903

 

 

 

1,699,643

 

 

 

1,708,017

 

 

 

1,714,473

 

Subscription Business:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total subscription pets enrolled (at period end)

 

1,082,412

 

 

 

1,066,354

 

 

 

1,052,845

 

 

 

1,041,212

 

 

 

1,032,042

 

 

 

1,020,934

 

 

 

1,006,168

 

 

 

991,426

 

Monthly average revenue per pet

$

82.01

 

 

$

79.93

 

 

$

77.53

 

 

$

76.02

 

 

$

74.27

 

 

$

71.72

 

 

$

69.79

 

 

$

67.07

 

Average pet acquisition cost (PAC)

$

290

 

 

$

276

 

 

$

267

 

 

$

261

 

 

$

243

 

 

$

231

 

 

$

207

 

 

$

217

 

Average monthly retention

 

98.33

%

 

 

98.29

%

 

 

98.28

%

 

 

98.25

%

 

 

98.29

%

 

 

98.34

%

 

 

98.41

%

 

 

98.49

%


The following table reflects the reconciliation of cash provided by operating activities to free cash flow (in thousands):

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Net cash provided by operating activities

$

29,238

 

 

$

15,296

 

 

$

60,226

 

 

$

24,585

 

Purchases of property, equipment, and internal-use software

 

(5,302

)

 

 

(1,914

)

 

 

(10,206

)

 

 

(7,858

)

Free cash flow

$

23,936

 

 

$

13,382

 

 

$

50,020

 

 

$

16,727

 


The following tables reflect the reconciliation between GAAP and non-GAAP measures (in thousands except percentages):

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Veterinary invoice expense

 

$

263,127

 

 

$

238,814

 

 

$

766,157

 

 

$

703,485

 

Less:

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

 

(666

)

 

 

(830

)

 

 

(2,188

)

 

 

(2,535

)

Other business cost of paying veterinary invoices(2)

 

 

(85,394

)

 

 

(82,507

)

 

 

(247,369

)

 

 

(239,342

)

Subscription cost of paying veterinary invoices (non-GAAP)

 

$

177,067

 

 

$

155,477

 

 

$

516,600

 

 

$

461,608

 

% of subscription revenue

 

 

70.1

%

 

 

71.0

%

 

 

71.0

%

 

 

73.4

%

 

 

 

 

 

 

 

 

 

Other cost of revenue

 

$

43,739

 

 

$

39,263

 

 

$

130,311

 

 

$

119,017

 

Less:

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

 

(579

)

 

 

(536

)

 

 

(1,661

)

 

 

(1,479

)

Other business variable expenses(2)

 

 

(20,702

)

 

 

(18,126

)

 

 

(62,969

)

 

 

(57,713

)

Subscription variable expenses (non-GAAP)

 

$

22,458

 

 

$

20,601

 

 

$

65,681

 

 

$

59,825

 

% of subscription revenue

 

 

8.9

%

 

 

9.4

%

 

 

9.0

%

 

 

9.5

%

 

 

 

 

 

 

 

 

 

Technology and development expense

 

$

9,887

 

 

$

7,933

 

 

$

26,545

 

 

$

23,083

 

General and administrative expense

 

 

18,311

 

 

 

16,977

 

 

 

58,325

 

 

 

46,903

 

Less:

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

 

(6,551

)

 

 

(5,258

)

 

 

(18,340

)

 

 

(14,465

)

Development expenses(3)

 

 

(1,199

)

 

 

(1,474

)

 

 

(3,551

)

 

 

(4,307

)

Fixed expenses (non-GAAP)

 

$

20,448

 

 

$

18,178

 

 

$

62,979

 

 

$

51,214

 

% of total revenue

 

 

5.6

%

 

 

5.6

%

 

 

5.9

%

 

 

5.4

%

 

 

 

 

 

 

 

 

 

New pet acquisition expense

 

$

21,946

 

 

$

18,308

 

 

$

62,305

 

 

$

53,025

 

Less:

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

 

(1,527

)

 

 

(1,503

)

 

 

(5,916

)

 

 

(5,426

)

Other business pet acquisition expense(2)

 

 

(5

)

 

 

(8

)

 

 

(82

)

 

 

(31

)

Subscription acquisition cost (non-GAAP)

 

$

20,414

 

 

$

16,797

 

 

$

56,307

 

 

$

47,568

 

% of subscription revenue

 

 

8.1

%

 

 

7.7

%

 

 

7.7

%

 

 

7.6

%

(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.
(2)Excludes the portion of stock-based compensation expense attributable to the other business segment
(3)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.


The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

 

 

2024

 

 

 

2025

 

 

 

2024

 

Operating income (loss)

$

5,859

 

 

$

1,746

 

 

$

6,700

 

 

$

(9,862

)

Non-GAAP expense adjustments

 

 

 

 

 

 

 

Acquisition cost

 

20,419

 

 

 

16,805

 

 

 

56,389

 

 

 

47,599

 

Stock-based compensation expense(1)

 

9,323

 

 

 

8,127

 

 

 

28,105

 

 

 

23,905

 

Development expenses(2)

 

1,199

 

 

 

1,474

 

 

 

3,551

 

 

 

4,307

 

Depreciation and amortization

 

4,051

 

 

 

4,381

 

 

 

11,804

 

 

 

12,542

 

Loss from investment in joint venture

 

 

 

 

(34

)

 

 

(305

)

 

 

(184

)

Total adjusted operating income (non-GAAP)

$

40,851

 

 

$

32,567

 

 

$

106,854

 

 

$

78,675

 

 

 

 

 

 

 

 

 

Subscription Business:

 

 

 

 

 

 

 

Subscription operating income (loss)

$

7,826

 

 

$

3,824

 

 

$

13,410

 

 

$

(4,109

)

Non-GAAP expense adjustments

 

 

 

 

 

 

 

Acquisition cost

 

20,414

 

 

 

16,797

 

 

 

56,307

 

 

 

47,568

 

Stock-based compensation expense(1)

 

7,234

 

 

 

6,215

 

 

 

22,250

 

 

 

18,723

 

Development expenses(2)

 

826

 

 

 

986

 

 

 

2,433

 

 

 

2,855

 

Depreciation and amortization

 

2,790

 

 

 

2,929

 

 

 

8,087

 

 

 

8,315

 

Subscription adjusted operating income (non-GAAP)

$

39,090

 

 

$

30,751

 

 

$

102,487

 

 

$

73,352

 

 

 

 

 

 

 

 

 

Other Business:

 

 

 

 

 

 

 

Other business operating loss

$

(1,967

)

 

$

(2,044

)

 

$

(6,405

)

 

$

(5,569

)

Non-GAAP expense adjustments

 

 

 

 

 

 

 

Acquisition cost

 

5

 

 

 

8

 

 

 

82

 

 

 

31

 

Stock-based compensation expense(1)

 

2,089

 

 

 

1,912

 

 

 

5,855

 

 

 

5,182

 

Development expenses(2)

 

373

 

 

 

488

 

 

 

1,118

 

 

 

1,452

 

Depreciation and amortization

 

1,261

 

 

 

1,452

 

 

 

3,717

 

 

 

4,227

 

Other business adjusted operating income (non-GAAP)

$

1,761

 

 

$

1,816

 

 

$

4,367

 

 

$

5,323

 

(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation in accordance with GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.

(2)Consists of costs related to product exploration and development that are pre-revenue and historically have been insignificant.


The following tables reflect the reconciliation of GAAP measures to non-GAAP measures (in thousands, except percentages):

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Subscription revenue

 

$

252,697

 

 

$

218,986

 

 

$

727,917

 

 

$

628,738

 

Subscription cost of paying veterinary invoices

 

 

177,067

 

 

 

155,477

 

 

 

516,600

 

 

 

461,608

 

Subscription variable expenses

 

 

22,458

 

 

 

20,601

 

 

 

65,681

 

 

 

59,825

 

Subscription fixed expenses*

 

 

14,082

 

 

 

12,157

 

 

 

43,149

 

 

 

33,953

 

Subscription adjusted operating income (non-GAAP)

 

$

39,090

 

 

$

30,751

 

 

$

102,487

 

 

$

73,352

 

 

 

 

 

 

 

 

 

 

Other business revenue

 

$

114,223

 

 

 

108,470

 

 

$

334,535

 

 

$

319,639

 

Other business cost of paying veterinary invoices

 

 

85,394

 

 

 

82,507

 

 

 

247,369

 

 

 

239,342

 

Other business variable expenses

 

 

20,702

 

 

 

18,126

 

 

 

62,969

 

 

 

57,713

 

Other business fixed expenses*

 

 

6,366

 

 

 

6,021

 

 

 

19,830

 

 

 

17,261

 

Other business adjusted operating income (non-GAAP)

 

$

1,761

 

 

$

1,816

 

 

$

4,367

 

 

$

5,323

 

 

 

 

 

 

 

 

 

 

Revenue

 

$

366,920

 

 

$

327,456

 

 

$

1,062,452

 

 

$

948,377

 

Cost of paying veterinary invoices

 

 

262,461

 

 

 

237,984

 

 

 

763,969

 

 

 

700,950

 

Variable expenses

 

 

43,160

 

 

 

38,727

 

 

 

128,650

 

 

 

117,538

 

Fixed expenses*

 

 

20,448

 

 

 

18,178

 

 

 

62,979

 

 

 

51,214

 

Total business adjusted operating income (non-GAAP)

 

$

40,851

 

 

$

32,567

 

 

$

106,854

 

 

$

78,675

 

 

 

 

 

 

 

 

 

 

As a percentage of revenue:

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

2025

 

2024

 

2025

 

2024

Subscription revenue

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Subscription cost of paying veterinary invoices

 

 

70.1

%

 

 

71.0

%

 

 

71.0

%

 

 

73.4

%

Subscription variable expenses

 

 

8.9

%

 

 

9.4

%

 

 

9.0

%

 

 

9.5

%

Subscription fixed expenses*

 

 

5.6

%

 

 

5.6

%

 

 

5.9

%

 

 

5.4

%

Subscription adjusted operating income (non-GAAP)

 

 

15.5

%

 

 

14.0

%

 

 

14.1

%

 

 

11.7

%

 

 

 

 

 

 

 

 

 

Other business revenue

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Other business cost of paying veterinary invoices

 

 

74.8

%

 

 

76.1

%

 

 

73.9

%

 

 

74.9

%

Other business variable expenses

 

 

18.1

%

 

 

16.7

%

 

 

18.8

%

 

 

18.1

%

Other business fixed expenses*

 

 

5.6

%

 

 

5.6

%

 

 

5.9

%

 

 

5.4

%

Other business adjusted operating income (non-GAAP)

 

 

1.5

%

 

 

1.7

%

 

 

1.3

%

 

 

1.7

%

 

 

 

 

 

 

 

 

 

Revenue

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

 

 

100.0

%

Cost of paying veterinary invoices

 

 

71.5

%

 

 

72.7

%

 

 

71.9

%

 

 

73.9

%

Variable expenses

 

 

11.8

%

 

 

11.8

%

 

 

12.1

%

 

 

12.4

%

Fixed expenses*

 

 

5.6

%

 

 

5.6

%

 

 

5.9

%

 

 

5.4

%

Total business adjusted operating income (non-GAAP)

 

 

11.1

%

 

 

9.9

%

 

 

10.1

%

 

 

8.3

%

 

 

 

 

 

 

 

 

 

*Fixed expenses represent shared services that support both our subscription and other business segments and, as such, are generally allocated to each segment pro-rata based on revenues.


Adjusted operating income is a non-GAAP financial measure that adjusts operating income (loss) to remove the effect of acquisition cost, development expenses, and gain (loss) from investment in joint venture. Non-cash items, such as stock-based compensation expense and depreciation and amortization, are also excluded. Acquisition cost, development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization are expected to remain recurring expenses for the foreseeable future, but are excluded from this metric to measure scale in other areas of the business. Management believes acquisition costs primarily represent the cost to acquire new subscribers and are driven by the amount of growth we choose to pursue based primarily on the amount of our adjusted operating income period over period. Accordingly, this measure is not indicative of our core operating income performance. We also exclude development expenses, gain (loss) from investment in joint venture, stock-based compensation expense, and depreciation and amortization because we do not view those items as reflective of our core operating income performance.

Management uses adjusted operating income and the margin on adjusted operating income to understand the effects of scale in its non-acquisition cost and development expenses and to plan future advertising expenditures, which are designed to acquire new pets. Management uses this measure as a principal way of understanding the operating performance of its business exclusive of acquisition cost and new product exploration and development initiatives.  Management believes disclosure of this metric provides investors with the same data that the Company employs in assessing its overall operations and that disclosure of this measure may provide useful information regarding the efficiency of our utilization of revenues, return on advertising dollars in the form of new subscribers and future use of available cash to support the continued growth of our business.

The following tables reflect the reconciliation of adjusted EBITDA to net income (loss) (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Nine Months Ended September 30,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2025

 

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

$

13,803

 

 

$

(11,289

)

 

 

 

 

 

 

 

 

 

 

 

 

Excluding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

28,105

 

 

 

23,906

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization expense

 

11,804

 

 

 

12,542

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

(9,141

)

 

 

(9,412

)

 

 

 

 

 

 

 

 

 

 

 

 

Interest expense

 

9,683

 

 

 

11,071

 

 

 

 

 

 

 

 

 

 

 

 

 

Income tax (benefit) expense

 

1,898

 

 

 

(43

)

 

 

 

 

 

 

 

 

 

 

 

 

Loss from equity method investment

 

 

 

 

(33

)

 

 

 

 

 

 

 

 

 

 

 

 

Realized gain on nonmonetary exchange of preferred stock investment

 

(7,783

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

48,369

 

 

$

26,742

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Sep. 30, 2025

 

Jun. 30, 2025

 

Mar. 31, 2025

 

Dec. 31, 2024

 

Sep. 30, 2024

 

Jun. 30, 2024

 

Mar. 31, 2024

 

Dec. 31, 2023

Net income (loss)

$

5,873

 

 

$

9,413

 

 

$

(1,483

)

 

$

1,656

 

 

$

1,425

 

 

$

(5,862

)

 

$

(6,852

)

 

$

(2,163

)

Excluding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation expense(1)

 

9,323

 

 

 

9,268

 

 

 

9,514

 

 

 

8,036

 

 

 

8,127

 

 

 

8,381

 

 

 

7,398

 

 

 

6,636

 

Depreciation and amortization expense

 

4,051

 

 

 

3,962

 

 

 

3,791

 

 

 

3,924

 

 

 

4,381

 

 

 

4,376

 

 

 

3,785

 

 

 

3,029

 

Interest income

 

(3,201

)

 

 

(3,105

)

 

 

(2,835

)

 

 

(2,999

)

 

 

(3,232

)

 

 

(3,135

)

 

 

(3,045

)

 

 

(2,842

)

Interest expense

 

2,790

 

 

 

3,682

 

 

 

3,211

 

 

 

3,427

 

 

 

3,820

 

 

 

3,655

 

 

 

3,596

 

 

 

3,697

 

Income tax (benefit) expense

 

726

 

 

 

1,133

 

 

 

39

 

 

 

38

 

 

 

39

 

 

 

(44

)

 

 

(38

)

 

 

130

 

Goodwill impairment charges

 

 

 

 

 

 

 

 

 

 

5,299

 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from equity method investment

 

 

 

 

 

 

 

 

 

 

 

 

 

(33

)

 

 

 

 

 

 

 

 

 

Realized gain on nonmonetary exchange of preferred stock investment

 

 

 

 

(7,783

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

19,562

 

 

$

16,570

 

 

$

12,237

 

 

$

19,381

 

 

$

14,527

 

 

$

7,371

 

 

$

4,844

 

 

$

8,487

 

(1)Trupanion employees may elect to take restricted stock units in lieu of cash payment for their bonuses. We account for such expense as stock-based compensation according to GAAP, but we do not include it in any non-GAAP adjustments. Stock-based compensation associated with bonuses was approximately $0.2 million and $0.7 million for the three and nine months ended September 30, 2025, respectively.


Contacts:

Investors:
Laura Bainbridge, Senior Vice President, Corporate Communications
Gil Melchior, Director, Investor Relations
Investor.Relations@trupanion.com

A figure accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7c8abb73-5c61-4b32-81f0-f781475ade6a